In today's medical field, cancer** is undergoing unprecedented transformation. Among them, targeting and immunity, as two emerging methods, have attracted much attention. Each of them has its own unique strengths and potentials, but who is better at cancer**? This article will explain it for you from multiple perspectives.
1. Targeting**: Precise attack on cancer cells
As the name suggests, targeting ** is to design the corresponding ** drug by targeting the molecular targets unique to cancer cells, so as to achieve precise strikes. The advantage of this method is that it is highly effective in killing cancer cells while causing less damage to normal cells. However, the limitations of targeting** are also obvious: once cancer cells are mutated, effective drugs may fail, leading to recurrence.
2. Immunity**: Activate the body's own immunity
Unlike targeting, immunity focuses on activating the patient's own immune system to attack cancer cells. The advantage of this method is that it has a long persistence, and once the immune system is activated, the patient has the potential to achieve long-term survival benefits. However, the disadvantages of immunity** should not be overlooked: its efficacy varies from individual to individual, and some patients may not benefit from it; At the same time, immunity may trigger a series of immune responses, resulting in varying degrees of illness in patients
3. Targeting the target
Targeting is the same as our traditional thinking, both are aimed at destroying tumors, the difference is that targeting is a targeted way of elimination, and most targeted drugs are now more and more clear when used, and the target is more accurate.
Immunity is also targeted in a sense, but unlike the previous anti-tumor principle, it does not target tumor cells, but immune cells. Immuno** drugs cannot directly destroy tumor cells, but by blocking the combination of immune cells and tumor cells, activate the immune system in the body that can destroy tumor cells, and then let a large number of immune cells reactivate and complete their due responsibilities.
If chemotherapy is an indiscriminate killing machine, then targeting** is precisely targeted special forces, and immunization** is the instructor who conducts mobilization training for special forces.
Fourth, the speed and time of onset
Because the targeting ** is aimed at tumor cells, it has a fast onset of effect, and the tumor will shrink significantly in a few weeks or even a few days, if it is used in patients with suitable indications, it can achieve high efficiency, fast onset, quickly alleviate some symptoms of the tumor, and improve the quality of life and survival of tumor patients. However, drug resistance is a thorny problem of targeting**, and due to the suppression and evolution of tumors, drug resistance will appear after a period of time.
Immunity** is different, it indirectly kills tumor cells by activating the immune system in the body, so the onset of action will be slow, such as PD-1, an immune checkpoint inhibitor, the onset time is usually about two months to three months. In addition, the immune** efficiency is not very high, generally speaking, only 10% 20%, which means that some tumors do not respond to immuno** drugs.
But as long as there is a response, patients will benefit in the long run; As long as it is effective, he lasts for a long time and can be used for a long time, and a small percentage of patients can even survive for a long time, or even **. This is one of the main reasons why patients are enthusiastic about immune**. Long-term follow-up data show that immunization** can lead to a long-term survival, significant survival for most lung cancer patients. The five-year average survival rate for NSCLC was around 6% before immunization**, and 18% after immunization**.